Symbiosis Pharmaceutical Services, a Scotland-based contract manufacturing organisation (CMO), has chosen ProSys Group for its expansion project after acquiring a new facility in Stirling.
The new facility will boost Symbiosis Pharmaceutical Services’s sterile manufacturing capacity
The Ireland-based provider of isolator technology and sampling systems to the bio-pharmaceutical market contributed the following features to the project:
- Fully validated Grade A environment inside the RABS
- Customised height to fit the existing cleanroom
- Completed the project within seven months
The new facility will boost Symbiosis Pharmaceutical Services’s sterile manufacturing capacity by increasing its batch size capabilities with the addition of automated sterile manufacturing production lines.
With the expansion, Symbiosis Pharmaceutical Services is enhancing operational flexibility
With the expansion, Symbiosis Pharmaceutical Services is enhancing operational flexibility to accommodate a range of GMP sterile manufacturing processes.
This puts the company in a better position to serve its global clients by accelerating the delivery of sterile injectable drug products to clinical trials and commercial markets.
In terms of funding, the project was backed by a £4.3M grant from Scottish Enterprise
Additionally, in terms of funding, the project was backed by a £4.3M grant from Scottish Enterprise, a non-departmental public body of the Scottish Government that encourages economic development, enterprise, innovation, international and investment in business.
The project is set to contribute to Scotland's life sciences industry by creating 50 new jobs and safeguarding 130 existing jobs.